Clarity Pharmaceuticals' Trial Win Over Telix Meets Biotech Sector Volatility
A head-to-head trial victory against the market-leading prostate cancer diagnostic drove a sharp rally, before broader biotech sentiment pulled the stock back down.
30 Jun 2026 · 3 min read
In short
Clarity Pharmaceuticals rallied 37-38% in October 2025 on trial data showing its prostate cancer diagnostic outperformed rival Telix Pharmaceuticals' incumbent product in head-to-head lesion detection.
The company signed a manufacturing agreement with Nucleus RadioPharma to produce up to 600,000 doses annually of its Cu-64 diagnostic isotope, enabling supply across all 50 US states and parts of Europe.
Fund managers including Perennial Partners attribute much of the stock's subsequent decline to broader biotech sector de-rating and tax-loss selling rather than any deterioration in trial results.
Clarity Pharmaceuticals rallied 37 to 38 percent in October on positive head-to-head trial data showing its prostate cancer diagnostic outperformed rival Telix Pharmaceuticals' incumbent product, before the stock steadily gave back those gains through a volatile year that fund managers largely attribute to broader biotech sentiment and technical selling rather than any deterioration in the underlying science.
A head-to-head win against the market leader
Blackwattle Investment Partners described Clarity as an emerging nuclear medicine company, with shares rising 37.6 percent in October after a positive trial result comparing its prostate cancer diagnostic head-to-head against the incumbent product from ASX-listed Telix Pharmaceuticals. Pengana Capital Group detailed the initial Co-PSMA study data, comparing Clarity's copper-64-based imaging agent with a gallium-68 agent similar to Telix's, showing a statistically significant increase in cancer lesions detected with Clarity's product, with full details expected at a conference in the first quarter of the following year. Endeavor Asset Management said the trial successfully met its primary endpoint, demonstrating statistically higher lesion detection, and confirmed a February switch from CSL into Clarity had proven effective, with the stock rising 44 percent by the time it exited the position after the trial outcome and re-rating met its valuation target.
The early results showed a statistically significant increase in cancer lesions detected with Clarity's product, compared to a Ga-68 agent similar to that used by Telix.
— Pengana Capital Group, Monthly Report, October 2025
A volatile stock that gives back gains on no news
Pengana Capital Group said the stock fell 26 percent in November on little news, while still expecting further data from both the Co-PSMA study and the SECURE prostate cancer therapeutic study in the first quarter, either of which could be a significant catalyst, with the best-case scenario involving FDA approval for the diagnostic. Blackwattle Investment Partners said the company held its AGM during the month with no new updates, and the share price contraction appeared to follow a broader move in growth stocks rather than any company-specific development.
A manufacturing deal, then more volatility
Pengana Capital Group said the stock fell 9 percent in April despite signing a manufacturing agreement with Nucleus RadioPharma to produce up to 600,000 doses annually of Cu-64, Clarity's prostate cancer diagnostic isotope, allowing it to supply all 50 US states and selected European locations, with FDA approval for the diagnostic still expected in the coming period. Perennial Partners called Clarity its largest portfolio detractor that month, describing the stock as decidedly volatile from month to month ahead of a catalyst-rich second half with several trial readouts expected.
Clarity fell 9% despite signing a manufacturing agreement with Nucleus RadioPharma to produce up to 600,000 doses annually of Cu64, its prostate cancer diagnostic isotope, allowing it to supply all 50 US states and selected locations in Europe.
— Pengana Capital Group, Monthly Report, April 2026
June's decline traced to tax selling, not fundamentals
Perennial Partners said the stock declined amid a broader de-rating of clinical-stage, pre-revenue Australian biotechnology names, as investors demanded greater near-term cash-generation certainty, but attributed the fall more to end-of-financial-year tax-loss selling and federal budget tax changes than to any identifiable fundamental reason.
What fund managers say they are watching next is progress toward FDA approval for the prostate cancer diagnostic, further Co-PSMA and SECURE study readouts expected in the catalyst-rich second half, delivery on the Nucleus RadioPharma manufacturing capacity of 600,000 doses a year, and whether sentiment toward pre-revenue biotech names broadly stabilises.
Questions
Why did Clarity Pharmaceuticals rally 37-38% in October 2025?
Clarity Pharmaceuticals rallied after releasing positive Co-PSMA study data showing its copper-64-based prostate cancer diagnostic detected statistically more cancer lesions than a comparable agent similar to rival Telix Pharmaceuticals' incumbent product.
What is Clarity Pharmaceuticals' manufacturing agreement with Nucleus RadioPharma?
Clarity Pharmaceuticals signed an agreement with Nucleus RadioPharma to produce up to 600,000 doses annually of its Cu-64 diagnostic isotope, enabling it to supply all 50 US states and selected locations in Europe.
Why has Clarity Pharmaceuticals' share price been so volatile?
Fund managers including Perennial Partners attribute much of the volatility to broader sentiment shifts affecting clinical-stage, pre-revenue Australian biotechnology names, along with tax-loss selling, rather than changes in the company's trial results.
7 managers, 34 comments, with each manager's latest recorded position.
See CU6